X-chromosome reactivation: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 52: Line 52:


== Mechanism ==
== Mechanism ==
The mechanisms of Xi reactivation remains unknown, including whether they share a common pathway or if different contexts leverage completely different pathways.<ref name=":4" /> It is thought that for XCR to be repressed, silencing of ''Xist'' expression is required but not sufficient. The erasure of chromatin modifications that maintain the heterochromatin of the Xi significantly contributes to XCR. [[H3K27me3]] and macroH2A, and their associated mechanisms of [[DNA methylation]] and [[histone]] [[deacetylation]], act as a barriers to XCR in the ICM.<ref name=":8" /> Deleting Xist RNA, demethylating DNA, and inhibiting histone hypoacetylation together increases reactivation in primary mouse embryonic fibroblasts on the gene level in a stochastic manner.<ref name=":6" />
The mechanisms of Xi reactivation remains unknown, including whether they share a common pathway or if different contexts leverage completely different pathways.<ref name=":4" /> It is thought that for XCR to be repressed, silencing of ''Xist'' expression is required but not sufficient<ref>{{Cite journal |last=Cantone |first=Irene |last2=Bagci |first2=Hakan |last3=Dormann |first3=Dirk |last4=Dharmalingam |first4=Gopuraja |last5=Nesterova |first5=Tatyana |last6=Brockdorff |first6=Neil |last7=Rougeulle |first7=Claire |last8=Vallot |first8=Celine |last9=Heard |first9=Edith |last10=Chaligne |first10=Ronan |last11=Merkenschlager |first11=Matthias |last12=Fisher |first12=Amanda G. |date=2016-11 |title=Ordered chromatin changes and human X chromosome reactivation by cell fusion-mediated pluripotent reprogramming |url=http://www.nature.com/articles/ncomms12354 |journal=Nature Communications |language=en |volume=7 |issue=1 |pages=12354 |doi=10.1038/ncomms12354 |issn=2041-1723 |pmc=PMC4987517 |pmid=27507283}}</ref>. The erasure of chromatin modifications that maintain the heterochromatin of the Xi significantly contributes to XCR. [[H3K27me3]] and macroH2A, and their associated mechanisms of [[DNA methylation]] and [[histone]] [[deacetylation]], act as a barriers to XCR in the ICM.<ref name=":8" /> Deleting Xist RNA, demethylating DNA, and inhibiting histone hypoacetylation together increases reactivation in primary mouse embryonic fibroblasts on the gene level in a stochastic manner.<ref name=":6" /><ref>{{Cite journal |last=Cantone |first=Irene |last2=Dharmalingam |first2=Gopuraja |last3=Chan |first3=Yi-Wah |last4=Kohler |first4=Anne-Celine |last5=Lenhard |first5=Boris |last6=Merkenschlager |first6=Matthias |last7=Fisher |first7=Amanda G. |date=2017-12 |title=Allele-specific analysis of cell fusion-mediated pluripotent reprograming reveals distinct and predictive susceptibilities of human X-linked genes to reactivation |url=http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1136-4 |journal=Genome Biology |language=en |volume=18 |issue=1 |pages=2 |doi=10.1186/s13059-016-1136-4 |issn=1474-760X}}</ref>


X reactivation can be induced and tolerated in mouse extra-embryonic tissues.<ref name=":4" /> For example, a mutation of the [[Polycomb protein EED]] leads to a lack of ''Xist'' RNA coating on the Xi and X reactivation in differentiated [[trophoblast]] stem cells.<ref>{{Cite journal |last1=Kalantry |first1=Sundeep |last2=Mills |first2=Kyle C. |last3=Yee |first3=Della |last4=Otte |first4=Arie P. |last5=Panning |first5=Barbara |last6=Magnuson |first6=Terry |date=2006-01-15 |title=The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation |journal=Nature Cell Biology |language=en |volume=8 |issue=2 |pages=195–202 |doi=10.1038/ncb1351 |issn=1476-4679 |pmc=1400591 |pmid=16415857}}</ref>
X reactivation can be induced and tolerated in mouse extra-embryonic tissues.<ref name=":4" /> For example, a mutation of the [[Polycomb protein EED]] leads to a lack of ''Xist'' RNA coating on the Xi and X reactivation in differentiated [[trophoblast]] stem cells.<ref>{{Cite journal |last1=Kalantry |first1=Sundeep |last2=Mills |first2=Kyle C. |last3=Yee |first3=Della |last4=Otte |first4=Arie P. |last5=Panning |first5=Barbara |last6=Magnuson |first6=Terry |date=2006-01-15 |title=The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation |journal=Nature Cell Biology |language=en |volume=8 |issue=2 |pages=195–202 |doi=10.1038/ncb1351 |issn=1476-4679 |pmc=1400591 |pmid=16415857}}</ref>

Revision as of 13:00, 14 December 2022

X chromosome reactivation (XCR) is the process by which the inactive X chromosome (the Xi) is re-activated in the cells of eutherian female mammals. Therian female mammalian cells have two X chromosomes, while males have only one, requiring X-chromosome inactivation (XCI) for sex-chromosome dosage compensation. In eutherians, XCI is the random inactivation of one of the X chromosomes, silencing its expression. Much of the scientific knowledge currently known about XCR comes from research limited to mouse models or stem cells.

Partial XCR may derepress one or more genes on the Xi, and the level of restored gene expression may not be as high as it would normally be on the active X chromosome (the Xa). Complete XCR restores the Xi to Xa and erases the epigenetic memory of XCI, meaning that inducing X-inactivation again will randomly select an X chromosome to silence, rather than deterministically silencing the original Xi.[1]

XCR is an emerging topic of interest for multiple reasons:[1]

  1. Reactivating silenced genes may be a therapy for X-linked diseases in heterozygous females, such as Rett syndrome,[2] or a therapy for cancer by reactivating silenced tumor suppressor genes
  2. XCR may be a contributing factor to human disorders, such as certain cancers
  3. Understanding the mechanisms of XCR will elucidate general gene regulation principles, and forge ahead in the study of gene silencing, epigenetic memory, and the role of long non-coding RNAs (lncRNAs)

History

History of X-inactivation

This section is an excerpt from X-inactivation § History.[edit]

In 1959 Susumu Ohno showed that the two X chromosomes of mammals were different: one appeared similar to the autosomes; the other was condensed and heterochromatic.[3] This finding suggested, independently to two groups of investigators, that one of the X chromosomes underwent inactivation.

In 1961, Mary Lyon proposed the random inactivation of one female X chromosome to explain the mottled phenotype of female mice heterozygous for coat color genes.[4] The Lyon hypothesis also accounted for the findings that one copy of the X chromosome in female cells was highly condensed, and that mice with only one copy of the X chromosome developed as infertile females. This suggested[5] to Ernest Beutler, studying heterozygous females for glucose-6-phosphate dehydrogenase (G6PD) deficiency, that there were two red cell populations of erythrocytes in such heterozygotes: deficient cells and normal cells,[6] depending on whether the inactivated X chromosome (in the nucleus of the red cell's precursor cell) contains the normal or defective G6PD allele.

History of X-reactivation

Early in the study of XCI in early embryonic development, the original state of the two X chromosomes and the mechanism by which they differentiated into the Xa and Xi was unknown. One hypothesis was that the chromosomes were inactive until one was activated. The other, favored hypothesis that was eventually validated was that both maternal and paternal X chromosomes are active until some mechanism inactivates one chromosome.[7]

As early as 1981, the concept of X reactivation appears in the literature, with a paper on induced XCR in somatic cell hybrid clones by 5-azacitidine treatment,[8] and a paper on XCR in mouse oocytes.[9]

Experiments originally showed that eliminating the X-inactive specific transcript (Xist) gene, a gene that encodes a lncRNA that mediates XCI, in post-XCI somatic cells did not result in detectable Xi reactivation. Therefore, it was believed that XCI, once established in somatic cells, was irreversible and that Xist, while required to initiate XCI, was not required to sustain it.[10] However, newer investigations using modern technologies have found evidence that Xist RNA is involved in the maintenance of XCI. For example, Zhang, et al. found that “Deleting Xist results in a loss of nucleolar association and an inability to maintain Xi heterochromatin, leading to Xi reactivation at the single gene level.”[11]

Unlike XCI, XCR lacks an appropriate in vitro system for study, limiting current research to mouse embryos and in vitro stem cell reprogramming.[12]

Biological Occurrences

During Development

See also: X-inactivation § Cycle of X-chromosome activation in rodents

In mice, Xi reactivation is known to occur in three developmental stages:[13]

  1. In the oocyte after fertilization, the paternal X chromosome is reactivated, reversing male meiotic sex chromosome inactivation (MSCI).
  2. In the inner cell mass (ICM) of the epiblast after imprinted XCI in preimplantation development, the Xi is reactivated.
  3. In migrating primordial germ cells (PGCs), Xi reactivation establishes two Xa's in female germ cells before oogenesis. Unlike the other two, here genomic imprinting is erased.

It is known that in the inner cell mass (the embryo proper) of mice, XCI occurs randomly, while in the extra-embryonic tissues, imprinted XCI deterministically inactivates the paternal X. In early mouse embryos, the paternal X chromosome is already partially silenced at the zygote stage by imprinted XCI, suggesting that sex-chromosome dosage compensation exists from conception. Following re-activation of the paternal X in the ICM, complete and random XCI occurs post-implantation.[14][15]

Regarding female mouse germ cells, mature mammalian oocytes were observed to have two active X chromosomes by studies that recorded twice the expression levels from the oocytes from XX female mice as opposed to XO mice in the 1960s.[16] To determine whether XCI never occurred in these cells, or if the Xi was reactivated post-XCI, Kratzer and Chapman found that oogonia have an Xi and an Xa, but the Xi is gradually reactivated shortly before entering the meiotic cycle on the eleventh day.[9]

In human development, X chromosome reactivation also occurs in PGCs.[17] In the ICM of human embryos, however, X reactivation does not occur, because humans do not have imprinted XCI, so XCI has yet to happen in this stage of development.[18]

In Cancer

Because only one X chromosome is expressed, genetic mutations that lead to cancer are dominant when they occur on the Xa, and silent on the Xi. Increased dosage of X-linked genes, by whole or partial replication of the Xa or by whole or partial loss of XCI, is linked to oncogenesis. Translocations between the Xi and autosomal chromosomes can result in the silencing of autosomal tumor suppressors or reactivation of X-linked oncogenes. X-linked genes may escape inactivation, which potential oncogenic consequences. Impaired XCI and skewed X-inactivation may also be associated with oncogenesis.[19]

Gain of an X chromosome,[20] Klinefelter syndrome,[21] and XX male syndrome[22] are risk factors linked to male breast cancer. In females, there is no evidence that trisomy X or tetrasomy X females are at higher risk of cancer.[19]

Breast cancer and ovarian cancer, particularly more aggressive strains, commonly lack an Xi and have two Xa's.[23] Breast cancer cells commonly have two identical Xa's, possibly from duplication of the original Xa and loss of the original Xi.[24] Gains of X chromosomes have been observed in many other cancers, including leukemia,[25] prostate cancer,[26][27] and intracranial germ cell cancers.[28] Potential mechanisms leading to this overexpression of X-linked genes include chromosome segregation errors, defects in general heterochromatin maintenance, and defects in Xi-specific silencing factors, the latter two of which would partially reactivate the Xi.[23]

In Stem Cell Reprogramming

The presence of two Xa's is a measure of the pluripotency, or ability to differentiate into many different cell types, of embryonic stem cells.[29] Cell hybrid experiments fusing somatic cells and stem cells in vitro resulted in reactivation of the entire Xi.[30][31][32][33]Reprogramming of mouse and human fibroblast cells to induced pluripotent stem cells (iPSCs) reactivates the Xi found in the original fibroblasts. If re-differentiated and XCI occurs again, the selection of the Xi is not randomized and the X that was the Xi in the starting fibroblast is inactivated, evidencing the incompleteness of X reactivation.[34] Reprogramming can be accomplished by nuclear cloning, cell fusion with pluripotent cells, or expression of pluripotency factors.[13] Factors implicated in XCI maintenance include origin recognition complex 2 (Orc2), heterochromatin protein 1 (HP1a),[35] macroH2A1,[36] and Bmil.[13] Disruption of Orc2 or HP1a function have both been shown to lead to partial Xi reactivation.[35]

Mechanism

The mechanisms of Xi reactivation remains unknown, including whether they share a common pathway or if different contexts leverage completely different pathways.[13] It is thought that for XCR to be repressed, silencing of Xist expression is required but not sufficient[37]. The erasure of chromatin modifications that maintain the heterochromatin of the Xi significantly contributes to XCR. H3K27me3 and macroH2A, and their associated mechanisms of DNA methylation and histone deacetylation, act as a barriers to XCR in the ICM.[18] Deleting Xist RNA, demethylating DNA, and inhibiting histone hypoacetylation together increases reactivation in primary mouse embryonic fibroblasts on the gene level in a stochastic manner.[38][39]

X reactivation can be induced and tolerated in mouse extra-embryonic tissues.[13] For example, a mutation of the Polycomb protein EED leads to a lack of Xist RNA coating on the Xi and X reactivation in differentiated trophoblast stem cells.[40]

Xist repression in XCR is thought to be induced by Tsix RNA.[41] Tsix deletion appears to decrease the efficiency of XCR in the ICM in vivo, but not in iPSC reprogramming.[42]

Timing of Gene Expression

Studies have elucidated some of the progression of XCR in the reversal of imprinted XCI in the mouse ICM,[43] of random XCI in iPSC reprogramming,[44] and in germ cell development.[45] XCR proceeds gradually, with sets of genes regaining expression at the early, mid, or late stage of XCR. At the initiation of X reactivation, early genes are transcriptionally activated and Xist repression starts. The reactivation of these early genes happens before complete Xist silencing, suggesting the latter is not necessary for the reactivation of some genes.[44] As XCR progresses, intermediate and late genes are transcriptionally activated, Xist RNA is lost, H3K27me3 is lost, and Tsix is reactivated. During this process, in genome topology there may possibly be acquisition of topologically associating domains (TADs), which are units of genome organization in 3D space, and loss of mega-domains. At completion, there is complete transcriptional reactivation of genes on the Xi, loss of epigenetic memory, DNA hypomethylation, fully established TADs, and if XCI is re-instated, the choice of Xi will be random.[1]

As a Potential Therapy

The human X chromosome contains a disproportionate number of genes associated with intellectual disability.[46] X-linked disorders in heterozygous female patients are a unique subject of study because they carry an X chromosome with the mutated disorder allele and an X chromosome with a healthy wild-type allele.[47] XCI randomly selects on X chromosome as the Xi, leaving the genes on the other X, the Xa, to be expressed.[48] Therefore, heterozygous female patients are a mosaic of healthy and diseased cells. In non-cell-autonomous X-linked disorders, such as hemophilia A,[49] the healthy cells can compensate for the diseased cells. In other disorders such as Kabuki syndrome, the mutation affects the cell such that cells carrying the healthy allele are more common (a skewed XCI pattern), reducing the severity of the disease.[50] However, in X-linked disorders where the healthy cells are insufficient to restore wild-type function, X chromosome reactivation may be a potential therapy. By reactivating the Xi in diseased cells, the previously unexpressed wild-type allele can regain some level of expression and restore function. Disorders that could hypothetically be treated by X reactivation include Rett syndrome,[51][52] CDKL5 deficiency disorder,[53] Fragile X syndrome, etc.[54][55][56]

Potential Risks and Concerns

XCI serves a central function in sex-chromosome dosage compensation. Xi reactivation currently doesn't target specific genes, but rather targets the entire chromosome, running the risk of overexpression of other X-linked genes and subsequent side effects. Treatments also may not be able to specifically target the Xi chromosome, instead causing genome-wide disruption of epigenetic patterns.[13]

XCI is essential for early embryonic development. For example, female mouse embryos that inherited a paternal germline Xist deletion had trophoblast cells where both X chromosomes were fully expressed, resulting in a lethal phenotype.[57] Pre-XCI Xist deletion in mouse zygotes can be tolerated to the extent that the embryos can be carried to term, but none survive past weaning as a result of issues with organ development.[58] However, these concerns may be mitigated by the fact that applications of X reactivation are more focused on post-XCI cells, past the early developmental stages.

Xi loss or Xi reactivation is associated with certain cancers. Xist deletion in the blood compartment of mice has been shown to cause hematologic cancers, suggesting an important role for Xist RNA and for XCI in cancer suppression.[59] In addition, while Xist deletion can be tolerated in the epithelial cells and the gut, the mouse becomes more susceptible to stress-induced gut cancer, suggesting Xist and XCI are protective against chronic stress.[60] Xist deletion in mouse brains have seen no negative effects in some studies.[61] The variation among organs and cell-types for tolerance of partial X reactivation currently appears to recommend a local approach targeting individual organs for X reactivation. For example, in neurodevelopmental disorders, X reactivation may be targeted to the brain and central nervous system.[62]

Research

In developing a treatment to reactivate the Xi, screens to identify single factors that inhibit XCI have listed many potential pharmacological targets to consider for further study.[63][64] However, XCI is complex and maintained by a diverse set of proteins[35] and multiple mechanisms, such as DNA methylation, histone hypoacetylation, and the role of Xist RNA.[38] More effective X reactivation may require a synergistic combination of factors, and studies have considered combinations of decitabine with Aurora kinase inhibitors,[65] Xist antisense oligonucleotides (ASOs),[66] and DNA TOP2A/TOP2B knockdown.[67] Some experimental synergistic combinations of drugs have outperformed any single factor for levels of X reactivation.[62]

References

  1. ^ a b c Talon, Irene; Janiszewski, Adrian; Chappell, Joel; Vanheer, Lotte; Pasque, Vincent (2019). "Recent Advances in Understanding the Reversal of Gene Silencing During X Chromosome Reactivation". Frontiers in Cell and Developmental Biology. 7: 169. doi:10.3389/fcell.2019.00169. ISSN 2296-634X. PMC 6733891. PMID 31552244.
  2. ^ Inácio, Patricia. "New Rett Therapies May Stem From X-chromosome Reactivation Findings". Retrieved 2022-08-08.
  3. ^ Ohno S, Kaplan WD, Kinosita R (October 1959). "Formation of the sex chromatin by a single X-chromosome in liver cells of Rattus norvegicus". Experimental Cell Research. 18 (2): 415–8. doi:10.1016/0014-4827(59)90031-X. PMID 14428474.
  4. ^ Lyon MF (April 1961). "Gene action in the X-chromosome of the mouse (Mus musculus L.)". Nature. 190 (4773): 372–3. Bibcode:1961Natur.190..372L. doi:10.1038/190372a0. PMID 13764598. S2CID 4146768.
  5. ^ Beutler E (January 2008). "Glucose-6-phosphate dehydrogenase deficiency: a historical perspective". Blood. 111 (1): 16–24. doi:10.1182/blood-2007-04-077412. PMID 18156501.
  6. ^ Beutler E, Yeh M, Fairbanks VF (January 1962). "The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker". Proceedings of the National Academy of Sciences of the United States of America. 48 (1): 9–16. Bibcode:1962PNAS...48....9B. doi:10.1073/pnas.48.1.9. PMC 285481. PMID 13868717.
  7. ^ Martin, Gail R.; Epstein, Charles J.; Travis, Bruce; Tucker, Georgianne; Yatziv, Shaul; Martin, David W.; Clift, Shirley; Cohen, Sara (January 1978). "X–chromosome inactivation during differentiation of female teratocarcinoma stem cells in vitro". Nature. 271 (5643): 329–333. Bibcode:1978Natur.271..329M. doi:10.1038/271329a0. ISSN 0028-0836. PMID 563984. S2CID 4156737.
  8. ^ Mohandas, T.; Sparkes, R. S.; Shapiro, L. J. (1981-01-23). "Reactivation of an Inactive Human X Chromosome: Evidence for X Inactivation by DNA Methylation". Science. 211 (4480): 393–396. Bibcode:1981Sci...211..393M. doi:10.1126/science.6164095. ISSN 0036-8075. PMID 6164095.
  9. ^ a b Kratzer, P G; Chapman, V M (May 1981). "X chromosome reactivation in oocytes of Mus caroli". Proceedings of the National Academy of Sciences. 78 (5): 3093–3097. Bibcode:1981PNAS...78.3093K. doi:10.1073/pnas.78.5.3093. ISSN 0027-8424. PMC 319506. PMID 6942418.
  10. ^ Wutz, Anton; Jaenisch, Rudolf (2000-04-01). "A Shift from Reversible to Irreversible X Inactivation Is Triggered during ES Cell Differentiation". Molecular Cell. 5 (4): 695–705. doi:10.1016/S1097-2765(00)80248-8. ISSN 1097-2765. PMID 10882105.
  11. ^ Zhang, Li-Feng; Huynh, Khanh D.; Lee, Jeannie T. (2007-05-18). "Perinucleolar Targeting of the Inactive X during S Phase: Evidence for a Role in the Maintenance of Silencing". Cell. 129 (4): 693–706. doi:10.1016/j.cell.2007.03.036. ISSN 0092-8674. PMID 17512404. S2CID 15918157.
  12. ^ Aizawa, Shiho; Nishimura, Ken; Mondejar, Gonzalo Seminario; Kumar, Arun; Bui, Phuong Linh; Tran, Yen Thi Hai; Kuno, Akihiro; Muratani, Masafumi; Kobayashi, Shin; Nabekura, Tsukasa; Shibuya, Akira (2022-01-11). "Early reactivation of clustered genes on the inactive X chromosome during somatic cell reprogramming". Stem Cell Reports. 17 (1): 53–67. doi:10.1016/j.stemcr.2021.11.008. ISSN 2213-6711. PMC 8758948. PMID 34919813.
  13. ^ a b c d e f Ohhata, Tatsuya; Wutz, Anton (July 2013). "Reactivation of the inactive X chromosome in development and reprogramming". Cellular and Molecular Life Sciences. 70 (14): 2443–2461. doi:10.1007/s00018-012-1174-3. ISSN 1420-682X. PMC 3689915. PMID 23052214.
  14. ^ Huynh, Khanh D.; Lee, Jeannie T. (December 2003). "Inheritance of a pre-inactivated paternal X chromosome in early mouse embryos". Nature. 426 (6968): 857–862. Bibcode:2003Natur.426..857H. doi:10.1038/nature02222. ISSN 1476-4687. PMID 14661031. S2CID 4312712.
  15. ^ Okamoto, Ikuhiro; Otte, Arie P.; Allis, C. David; Reinberg, Danny; Heard, Edith (2004-01-30). "Epigenetic Dynamics of Imprinted X Inactivation During Early Mouse Development". Science. 303 (5658): 644–649. Bibcode:2004Sci...303..644O. doi:10.1126/science.1092727. ISSN 0036-8075. PMID 14671313. S2CID 26326026.
  16. ^ Epstein, Charles J. (1969-03-07). "Mammalian Oocytes: X Chromosome Activity". Science. 163 (3871): 1078–1079. Bibcode:1969Sci...163.1078E. doi:10.1126/science.163.3871.1078. ISSN 0036-8075. PMID 5764873. S2CID 20129356.
  17. ^ von Meyenn, Ferdinand; Reik, Wolf (2015-06-04). "Forget the Parents: Epigenetic Reprogramming in Human Germ Cells". Cell. 161 (6): 1248–1251. doi:10.1016/j.cell.2015.05.039. ISSN 0092-8674. PMID 26046435. S2CID 13938537.
  18. ^ a b Okamoto, Ikuhiro; Patrat, Catherine; Thépot, Dominique; Peynot, Nathalie; Fauque, Patricia; Daniel, Nathalie; Diabangouaya, Patricia; Wolf, Jean-Philippe; Renard, Jean-Paul; Duranthon, Véronique; Heard, Edith (April 2011). "Eutherian mammals use diverse strategies to initiate X-chromosome inactivation during development". Nature. 472 (7343): 370–374. Bibcode:2011Natur.472..370O. doi:10.1038/nature09872. ISSN 1476-4687. PMID 21471966. S2CID 121019.
  19. ^ a b Spatz, Alain; Borg, Christophe; Feunteun, Jean (August 2004). "X-Chromosome Genetics and Human Cancer". Nature Reviews Cancer. 4 (8): 617–629. doi:10.1038/nrc1413. ISSN 1474-1768. PMID 15286741. S2CID 40468014.
  20. ^ Rudas, Margarethe; Schmidinger, Manuela; Wenzel, Catharina; Okamoto, Ichiro; Budinsky, Alexandra; Fazeny, Barbara; Marosi, Christine (2000-09-01). "Karyotypic Findings in Two Cases of Male Breast Cancer". Cancer Genetics and Cytogenetics. 121 (2): 190–193. doi:10.1016/S0165-4608(00)00254-5. ISSN 0165-4608. PMID 11063806.
  21. ^ Evans, D. B.; Crichlow, R. W. (1987-07-01). "Carcinoma of the Male Breast And Klinefelter's Syndrome: Is There an Association?". CA: A Cancer Journal for Clinicians. 37 (4): 246–251. doi:10.3322/canjclin.37.4.246. ISSN 0007-9235. PMID 3111653. S2CID 32844495.
  22. ^ Hado, H. S. H.; Helmy, S. W.; Klemm, K.; Miller, P.; Elhadd, T. A. (November 2003). "XX male: a rare cause of short stature, infertility, gynaecomastia and carcinoma of the breast". International Journal of Clinical Practice. 57 (9): 844–845. ISSN 1368-5031. PMID 14686579.
  23. ^ a b Pageau, Gayle J.; Hall, Lisa L.; Ganesan, Shridar; Livingston, David M.; Lawrence, Jeanne B. (August 2007). "The disappearing Barr body in breast and ovarian cancers". Nature Reviews Cancer. 7 (8): 628–633. doi:10.1038/nrc2172. ISSN 1474-1768. PMID 17611545. S2CID 21683640.
  24. ^ Wang, Nancy; Cedrone, Edward; Skuse, Gary R.; Insel, Richard; Dry, Jane (1990-06-01). "Two identical active X chromosomes in human mammary carcinoma cells". Cancer Genetics and Cytogenetics. 46 (2): 271–280. doi:10.1016/0165-4608(90)90112-N. ISSN 0165-4608. PMID 1971194.
  25. ^ Yamamoto, Katsuya; Nagata, Kaoru; Kida, Aiko; Hamaguchi, Hiroyuki (2002-04-01). "Acquired gain of an X chromosome as the sole abnormality in the blast crisis of chronic neutrophilic leukemia". Cancer Genetics and Cytogenetics. 134 (1): 84–87. doi:10.1016/S0165-4608(01)00603-3. ISSN 0165-4608. PMID 11996803.
  26. ^ Koivisto, P.; Hyytinen, E.; Palmberg, C.; Tammela, T.; Visakorpi, T.; Isola, J.; Kallioniemi, O. P. (December 1995). "Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy". The American Journal of Pathology. 147 (6): 1608–1614. ISSN 0002-9440. PMC 1869969. PMID 7495286.
  27. ^ Visakorpi, T.; Hyytinen, E.; Kallioniemi, A.; Isola, J.; Kallioniemi, O. P. (September 1994). "Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization". The American Journal of Pathology. 145 (3): 624–630. ISSN 0002-9440. PMC 1890337. PMID 8080044.
  28. ^ Okada, Yoshifumi; Nishikawa, Ryo; Matsutani, Masao; Louis, David N. (June 2002). "Hypomethylated X Chromosome Gain and Rare Isochromosome 12p in Diverse Intracranial Germ Cell Tumors". Journal of Neuropathology & Experimental Neurology. 61 (6): 531–538. doi:10.1093/jnen/61.6.531. ISSN 0022-3069. PMID 12071636.
  29. ^ Hysolli, Eriona; Tanaka, Yoshiaki; Kim, Kun-Yong; Jung, Yong Wook; Park, In-Hyun (2012-01-15). "The lesser known story of X chromosome reactivation". Cell Cycle. 11 (2): 229–235. doi:10.4161/cc.11.2.18998. ISSN 1538-4101. PMC 3293375. PMID 22234239.
  30. ^ Takagi, Nobuo; Yoshida, Mitsuaki A.; Sugawara, Osamu; Sasaki, Motomichi (1983-10-01). "Reversal of X-inactivation in female mouse somatic cells hybridized with murine teratocarcinoma stem cells in vitro". Cell. 34 (3): 1053–1062. doi:10.1016/0092-8674(83)90563-9. ISSN 0092-8674. PMID 6627391. S2CID 26700607.
  31. ^ Silva, José; Chambers, Ian; Pollard, Steven; Smith, Austin (June 2006). "Nanog promotes transfer of pluripotency after cell fusion". Nature. 441 (7096): 997–1001. Bibcode:2006Natur.441..997S. doi:10.1038/nature04914. ISSN 1476-4687. PMID 16791199. S2CID 4352052.
  32. ^ Tada, M.; Takahama, Y.; Abe, K.; Nakatsuji, N.; Tada, T. (2001-10-02). "Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells". Current Biology. 11 (19): 1553–1558. doi:10.1016/s0960-9822(01)00459-6. ISSN 0960-9822. PMID 11591326. S2CID 2195676.
  33. ^ Cantone, Irene; Bagci, Hakan; Dormann, Dirk; Dharmalingam, Gopuraja; Nesterova, Tatyana; Brockdorff, Neil; Rougeulle, Claire; Vallot, Celine; Heard, Edith; Chaligne, Ronan; Merkenschlager, Matthias; Fisher, Amanda G. (2016-11). "Ordered chromatin changes and human X chromosome reactivation by cell fusion-mediated pluripotent reprogramming". Nature Communications. 7 (1): 12354. doi:10.1038/ncomms12354. ISSN 2041-1723. PMC 4987517. PMID 27507283. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
  34. ^ Sahakyan, Anna; Kim, Rachel; Chronis, Constantinos; Sabri, Shan; Bonora, Giancarlo; Theunissen, Thorold W.; Kuoy, Edward; Langerman, Justin; Clark, Amander T.; Jaenisch, Rudolf; Plath, Kathrin (2017-01). "Human Naive Pluripotent Stem Cells Model X Chromosome Dampening and X Inactivation". Cell Stem Cell. 20 (1): 87–101. doi:10.1016/j.stem.2016.10.006. PMC 5218861. PMID 27989770. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
  35. ^ a b c Chan, Kui Ming; Zhang, Hui; Malureanu, Liviu; van Deursen, Jan; Zhang, Zhiguo (2011-10-04). "Diverse factors are involved in maintaining X chromosome inactivation". Proceedings of the National Academy of Sciences. 108 (40): 16699–16704. Bibcode:2011PNAS..10816699C. doi:10.1073/pnas.1107616108. ISSN 0027-8424. PMC 3189073. PMID 21940502.
  36. ^ Hernández-Muñoz, Inmaculada; Lund, Anders H.; van der Stoop, Petra; Boutsma, Erwin; Muijrers, Inhua; Verhoeven, Els; Nusinow, Dmitri A.; Panning, Barbara; Marahrens, York; van Lohuizen, Maarten (2005-05-24). "Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase". Proceedings of the National Academy of Sciences. 102 (21): 7635–7640. doi:10.1073/pnas.0408918102. ISSN 0027-8424. PMC 1140410. PMID 15897469.
  37. ^ Cantone, Irene; Bagci, Hakan; Dormann, Dirk; Dharmalingam, Gopuraja; Nesterova, Tatyana; Brockdorff, Neil; Rougeulle, Claire; Vallot, Celine; Heard, Edith; Chaligne, Ronan; Merkenschlager, Matthias; Fisher, Amanda G. (2016-11). "Ordered chromatin changes and human X chromosome reactivation by cell fusion-mediated pluripotent reprogramming". Nature Communications. 7 (1): 12354. doi:10.1038/ncomms12354. ISSN 2041-1723. PMC 4987517. PMID 27507283. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
  38. ^ a b Csankovszki, Györgyi; Nagy, András; Jaenisch, Rudolf (2001-05-14). "Synergism of Xist Rna, DNA Methylation, and Histone Hypoacetylation in Maintaining X Chromosome Inactivation". Journal of Cell Biology. 153 (4): 773–784. doi:10.1083/jcb.153.4.773. ISSN 0021-9525. PMC 2192370. PMID 11352938.
  39. ^ Cantone, Irene; Dharmalingam, Gopuraja; Chan, Yi-Wah; Kohler, Anne-Celine; Lenhard, Boris; Merkenschlager, Matthias; Fisher, Amanda G. (2017-12). "Allele-specific analysis of cell fusion-mediated pluripotent reprograming reveals distinct and predictive susceptibilities of human X-linked genes to reactivation". Genome Biology. 18 (1): 2. doi:10.1186/s13059-016-1136-4. ISSN 1474-760X. {{cite journal}}: Check date values in: |date= (help)CS1 maint: unflagged free DOI (link)
  40. ^ Kalantry, Sundeep; Mills, Kyle C.; Yee, Della; Otte, Arie P.; Panning, Barbara; Magnuson, Terry (2006-01-15). "The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation". Nature Cell Biology. 8 (2): 195–202. doi:10.1038/ncb1351. ISSN 1476-4679. PMC 1400591. PMID 16415857.
  41. ^ Ohhata, Tatsuya; Senner, Claire E.; Hemberger, Myriam; Wutz, Anton (2011-08-15). "Lineage-specific function of the noncoding Tsix RNA for Xist repression and Xi reactivation in mice". Genes & Development. 25 (16): 1702–1715. doi:10.1101/gad.16997911. ISSN 0890-9369. PMC 3165935. PMID 21852535. S2CID 25266286.
  42. ^ Payer, Bernhard; Rosenberg, Michael; Yamaji, Masashi; Yabuta, Yukihiro; Koyanagi-Aoi, Michiyo; Hayashi, Katsuhiko; Yamanaka, Shinya; Saitou, Mitinori; Lee, Jeannie T. (2013-12-26). "Tsix RNA and the Germline Factor, PRDM14, Link X Reactivation and Stem Cell Reprogramming". Molecular Cell. 52 (6): 805–818. doi:10.1016/j.molcel.2013.10.023. ISSN 1097-2765. PMC 3950835. PMID 24268575.
  43. ^ Borensztein, Maud; Okamoto, Ikuhiro; Syx, Laurène; Guilbaud, Guillaume; Picard, Christel; Ancelin, Katia; Galupa, Rafael; Diabangouaya, Patricia; Servant, Nicolas; Barillot, Emmanuel; Surani, Azim (2017-11-03). "Contribution of epigenetic landscapes and transcription factors to X-chromosome reactivation in the inner cell mass". Nature Communications. 8 (1): 1297. Bibcode:2017NatCo...8.1297B. doi:10.1038/s41467-017-01415-5. ISSN 2041-1723. PMC 5670228. PMID 29101321.
  44. ^ a b Janiszewski, Adrian; Talon, Irene; Chappell, Joel; Collombet, Samuel; Song, Juan; Geest, Natalie De; To, San Kit; Bervoets, Greet; Marin-Bejar, Oskar; Provenzano, Caterina; Vanheer, Lotte (2019-10-01). "Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming". Genome Research. 29 (10): 1659–1672. doi:10.1101/gr.249706.119. ISSN 1088-9051. PMC 6771397. PMID 31515287.
  45. ^ Sugimoto, Michihiko; Abe, Kuniya (2007-07-27). "X Chromosome Reactivation Initiates in Nascent Primordial Germ Cells in Mice". PLOS Genetics. 3 (7): e116. doi:10.1371/journal.pgen.0030116. ISSN 1553-7404. PMC 1950944. PMID 17676999.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  46. ^ Skuse, David H. (2005-04-15). "X-linked genes and mental functioning". Human Molecular Genetics. 14 (suppl_1): R27–R32. doi:10.1093/hmg/ddi112. ISSN 1460-2083. PMID 15809269.
  47. ^ Migeon, Barbara R. (2020-07-01). "X-linked diseases: susceptible females". Genetics in Medicine. 22 (7): 1156–1174. doi:10.1038/s41436-020-0779-4. ISSN 1098-3600. PMC 7332419. PMID 32284538.
  48. ^ Starmer, Joshua; Magnuson, Terry (2009-01-01). "A new model for random X chromosome inactivation". Development. 136 (1): 1–10. doi:10.1242/dev.025908. ISSN 1477-9129. PMC 2630377. PMID 19036804.
  49. ^ Franchini, Massimo; Mannucci, Pier Mannuccio (2012-05-02). "Past, present and future of hemophilia: a narrative review". Orphanet Journal of Rare Diseases. 7 (1): 24. doi:10.1186/1750-1172-7-24. ISSN 1750-1172. PMC 3502605. PMID 22551339.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  50. ^ Lederer, Damien; Grisart, Bernard; Digilio, Maria Cristina; Benoit, Valérie; Crespin, Marianne; Ghariani, Sophie Claire; Maystadt, Isabelle; Dallapiccola, Bruno; Verellen-Dumoulin, Christine (2012-01-13). "Deletion of KDM6A, a Histone Demethylase Interacting with MLL2, in Three Patients with Kabuki Syndrome". The American Journal of Human Genetics. 90 (1): 119–124. doi:10.1016/j.ajhg.2011.11.021. ISSN 0002-9297. PMC 3257878. PMID 22197486.
  51. ^ Lyst, Matthew J.; Bird, Adrian (May 2015). "Rett syndrome: a complex disorder with simple roots". Nature Reviews Genetics. 16 (5): 261–275. doi:10.1038/nrg3897. ISSN 1471-0064. PMID 25732612. S2CID 20494772.
  52. ^ Ip, Jacque P. K.; Mellios, Nikolaos; Sur, Mriganka (June 2018). "Rett syndrome: insights into genetic, molecular and circuit mechanisms". Nature Reviews Neuroscience. 19 (6): 368–382. doi:10.1038/s41583-018-0006-3. hdl:1721.1/127274. ISSN 1471-0048. PMC 6402579. PMID 29740174.
  53. ^ Weaving, Linda S.; Christodoulou, John; Williamson, Sarah L.; Friend, Kathie L.; McKenzie, Olivia L. D.; Archer, Hayley; Evans, Julie; Clarke, Angus; Pelka, Gregory J.; Tam, Patrick P. L.; Watson, Catherine (2004-12-01). "Mutations of CDKL5 Cause a Severe Neurodevelopmental Disorder with Infantile Spasms and Mental Retardation". The American Journal of Human Genetics. 75 (6): 1079–1093. doi:10.1086/426462. ISSN 0002-9297. PMC 1182143. PMID 15492925.
  54. ^ Blok, Lot Snijders; Madsen, Erik; Juusola, Jane; Gilissen, Christian; Baralle, Diana; Reijnders, Margot R. F.; Venselaar, Hanka; Helsmoortel, Céline; Cho, Megan T.; Hoischen, Alexander; Vissers, Lisenka E. L. M. (2015-08-06). "Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling". The American Journal of Human Genetics. 97 (2): 343–352. doi:10.1016/j.ajhg.2015.07.004. ISSN 0002-9297. PMC 4573244. PMID 26235985.
  55. ^ Reijnders, Margot R. F.; Zachariadis, Vasilios; Latour, Brooke; Jolly, Lachlan; Mancini, Grazia M.; Pfundt, Rolph; Wu, Ka Man; van Ravenswaaij-Arts, Conny M. A.; Veenstra-Knol, Hermine E.; Anderlid, Britt-Marie M.; Wood, Stephen A. (2016-02-04). "De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations". The American Journal of Human Genetics. 98 (2): 373–381. doi:10.1016/j.ajhg.2015.12.015. ISSN 0002-9297. PMC 4746365. PMID 26833328.
  56. ^ Lange, Iris M. de; Helbig, Katherine L.; Weckhuysen, Sarah; Møller, Rikke S.; Velinov, Milen; Dolzhanskaya, Natalia; Marsh, Eric; Helbig, Ingo; Devinsky, Orrin; Tang, Sha; Mefford, Heather C. (2016-12-01). "De novo mutations of KIAA2022 in females cause intellectual disability and intractable epilepsy". Journal of Medical Genetics. 53 (12): 850–858. doi:10.1136/jmedgenet-2016-103909. ISSN 0022-2593. PMC 5264224. PMID 27358180.
  57. ^ Marahrens, Y; Panning, B; Dausman, J; Strauss, W; Jaenisch, R (1997-01-15). "Xist-deficient mice are defective in dosage compensation but not spermatogenesis". Genes & Development. 11 (2): 156–166. doi:10.1101/gad.11.2.156. ISSN 0890-9369. PMID 9009199. S2CID 36848488.
  58. ^ Yang, Lin; Kirby, James E.; Sunwoo, Hongjae; Lee, Jeannie T. (2016-08-01). "Female mice lacking Xist RNA show partial dosage compensation and survive to term". Genes & Development. 30 (15): 1747–1760. doi:10.1101/gad.281162.116. ISSN 0890-9369. PMC 5002979. PMID 27542829.
  59. ^ Yildirim, Eda; Kirby, James E.; Brown, Diane E.; Mercier, Francois E.; Sadreyev, Ruslan I.; Scadden, David T.; Lee, Jeannie T. (2013-02-14). "Xist RNA Is a Potent Suppressor of Hematologic Cancer in Mice". Cell. 152 (4): 727–742. doi:10.1016/j.cell.2013.01.034. ISSN 0092-8674. PMC 3875356. PMID 23415223.
  60. ^ Yang, Lin; Yildirim, Eda; Kirby, James E.; Press, William; Lee, Jeannie T. (2020-02-25). "Widespread organ tolerance to Xist loss and X reactivation except under chronic stress in the gut". Proceedings of the National Academy of Sciences. 117 (8): 4262–4272. Bibcode:2020PNAS..117.4262Y. doi:10.1073/pnas.1917203117. ISSN 0027-8424. PMC 7049159. PMID 32041873.
  61. ^ Carrette, Lieselot L. G.; Wang, Chen-Yu; Wei, Chunyao; Press, William; Ma, Weiyuan; Kelleher, Raymond J.; Lee, Jeannie T. (2018-01-23). "A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders". Proceedings of the National Academy of Sciences. 115 (4): E668–E675. Bibcode:2018PNAS..115E.668C. doi:10.1073/pnas.1715124115. ISSN 0027-8424. PMC 5789928. PMID 29282321.
  62. ^ a b Grimm, Niklas-Benedikt; Lee, Jeannie T. (2022-03-02). "Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome". Trends in Genetics. 38 (9): 920–943. doi:10.1016/j.tig.2022.01.007. ISSN 0168-9525. PMID 35248405. S2CID 247252984.
  63. ^ Sripathy, Smitha; Leko, Vid; Adrianse, Robin L.; Loe, Taylor; Foss, Eric J.; Dalrymple, Emily; Lao, Uyen; Gatbonton-Schwager, Tonibelle; Carter, Kelly T.; Payer, Bernhard; Paddison, Patrick J. (2017-02-14). "Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP/TGF-β superfamily as a regulator of XIST expression". Proceedings of the National Academy of Sciences. 114 (7): 1619–1624. Bibcode:2017PNAS..114.1619S. doi:10.1073/pnas.1621356114. ISSN 0027-8424. PMC 5321041. PMID 28143937.
  64. ^ Bhatnagar, Sanchita; Zhu, Xiaochun; Ou, Jianhong; Lin, Ling; Chamberlain, Lynn; Zhu, Lihua J.; Wajapeyee, Narendra; Green, Michael R. (2014-09-02). "Genetic and pharmacological reactivation of the mammalian inactive X chromosome". Proceedings of the National Academy of Sciences. 111 (35): 12591–12598. Bibcode:2014PNAS..11112591B. doi:10.1073/pnas.1413620111. ISSN 0027-8424. PMC 4156765. PMID 25136103.
  65. ^ Lessing, Derek; Dial, Thomas O.; Wei, Chunyao; Payer, Bernhard; Carrette, Lieselot L. G.; Kesner, Barry; Szanto, Attila; Jadhav, Ajit; Maloney, David J.; Simeonov, Anton; Theriault, Jimmy (2016-12-13). "A high-throughput small molecule screen identifies synergism between DNA methylation and Aurora kinase pathways for X reactivation". Proceedings of the National Academy of Sciences. 113 (50): 14366–14371. Bibcode:2016PNAS..11314366L. doi:10.1073/pnas.1617597113. ISSN 0027-8424. PMC 5167172. PMID 28182563.
  66. ^ Mira-Bontenbal, H.; Tan, B.; Gontan, C.; Goossens, S.; Boers, R.G.; Boers, J.B.; Dupont, C.; van Royen, M.E.; IJcken, W.F.J.; French, P.; Bedalov, A. (March 2022). "Genetic and epigenetic determinants of reactivation of Mecp2 and the inactive X chromosome in neural stem cells". Stem Cell Reports. 17 (3): 693–706. doi:10.1016/j.stemcr.2022.01.008. PMC 9039756. PMID 35148843.
  67. ^ Minajigi, Anand; Froberg, John E.; Wei, Chunyao; Sunwoo, Hongjae; Kesner, Barry; Colognori, David; Lessing, Derek; Payer, Bernhard; Boukhali, Myriam; Haas, Wilhelm; Lee, Jeannie T. (2015-07-17). "A comprehensive Xist interactome reveals cohesin repulsion and an RNA-directed chromosome conformation". Science. 349 (6245): aab2276. doi:10.1126/science.aab2276. ISSN 0036-8075. PMC 4845908. PMID 26089354.
Retrieved from "https://en.wikipedia.org/w/index.php?title=X-chromosome_reactivation&oldid=1127392404"